This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Tivopath (Oncology)

AVEO Pharmaceuticals, Inc.

Drug Names(s): AV-951, KRN951, ASP4130, tivozanib, r N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5- methyl-3-isoxazolyl) urea hydrochloride monohydrate

Description: AV-951 (N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) urea hydrochloride monohydrate) is an inhibitor of VEGF receptors 1, 2 and 3, with picomolar inhibitory activity against all three receptors. Angiogenesis inhibition has demonstrated benefit for patients with a wide range of cancer types, including renal cell carcinoma, metastatic breast cancer, colorectal cancer, and non-small cell lung cancer. Due to its specificity, AVEO believes AV-951 may be more readily combined with standard chemotherapy as well as other targeted therapies, potentially increasing the breadth of its clinical utility.

BioMedTracker has two separate profiles for the oncology and ophthalmology programs of tivozanib. Tivopath for ophthalmology can be seen here.

Deal Structure: Revenue splits for this drug are BioMedTracker estimates.

Tivozanib was originally developed by Kirin Brewery (Kyowa Hakko Kirin).

Kirin and AVEO
In December 2006, AVEO acquired an exclusive license to develop and commercialize KRN951 in all territories outside of Asia. Financial terms of the agreement were not disclosed.

AVEO and Astellas
In February 2011, Astellas and AVEO Pharmaceuticals entered into a worldwide agreement outside of Asia to develop and commercialize tivozanib for the treatment of a broad range of cancers.

AVEO will receive an initial cash payment of $125 million, composed of a $75 million license fee and $50 million in research and development funding. AVEO is also eligible to receive approximately $1.3 billion in potential milestones comprised of $575 million in clinical and regulatory milestones, including $90 million in connection with the regulatory filings and market approval of tivozanib in RCC, as well as...See full deal structure in Biomedtracker

Partners: Astellas Pharma, Inc. Kyowa Hakko Kirin Co., Ltd. EUSA Pharma Ltd.


Tivopath (Oncology) News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug